Cancer Control最新文献

{"title":"The Essential Nature of Social Work in Cancer Control.","authors":"Brad Zebrack, Anao Zhang, Lauren V Ghazal, Nina Francis-Levin, Rachel E Brandon","doi":"10.1177/10732748251353081","DOIUrl":"10.1177/10732748251353081","url":null,"abstract":"<p><p>The conditions in which people are born, live, learn, work, play, worship, and age affect a range of health, functioning, and quality-of-life outcomes, and contribute to social needs across the cancer control continuum. To address these needs, advance the quality of cancer care, and achieve health equity, cancer care clinicians must possess comprehensive knowledge and skills to mitigate the effects of social determinants of health on patient outcomes. This knowledge should also encompass an understanding of how racism, sexism, and discrimination - along with exposures to trauma - also influence patient behaviors and outcomes, given evidence of their effects on population health. For over 100 years, social workers have comprised an essential workforce that is duly educated and trained to identify social needs and improve patient outcomes within the context of health care service delivery, and cancer care in particular. Oriented to an ecological framework, social workers are adept at identifying and mitigating the negative effects of the social determinants of health on individual knowledge, attitudes, beliefs, and behaviors, with the intent of improving results for people at risk for or diagnosed with cancer. Social workers are professionally trained for organizing communities, understanding and intervening upon social systems (including families, organizations, and institutions), providing emotional support and mental health counseling, and advocating for programs and policies that best serve patients, families, and communities. Thus, social workers play a critical role in service delivery across the cancer control continuum.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251353081"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of E-Health Use on Cancer Screening Mediated Through Cancer Worry and Fatalism: A Cross-Sectional Study of Older Adults.","authors":"Yu Zheng, Jiazheng Zayn Wang, Yingxia Zhu, Xinshu Zhao","doi":"10.1177/10732748251355831","DOIUrl":"10.1177/10732748251355831","url":null,"abstract":"<p><p>IntroductionCancer has been one of the major causes of death among older adults. Cancer screening is key for early detection, which may help prevent or alleviate cancer. E-health platforms have been a main discriminator of cancer-related knowledge. The Health Belief Model indicates an association between individual behaviors, intentions, and other psychological factors. Understanding the psychological mechanisms that mediate the effect of E-health use (EHU) on cancer screening intention is crucial for cancer prevention and treatment among older adults.MethodsCross-sectional data were from the National Trends in Health Information Survey 6 (HINTS6). Respondents aged 65-74 years were selected for the study, and the final sample size, excluding missing values, was 925. This study used a parallel mediation model to analyze the mediating role of psychological mechanisms through cancer worry and cancer fatalism. Regression analysis was conducted using SPSS to test the parallel mediation model.ResultsThe study found a direct (<i>b</i> = .25, <i>b</i>_<i>p</i> = .25, <i>P</i> < .001) positive association between E-health use and cancer screening intentions. In addition, this study revealed a parallel indirect association between E-health use and cancer screening intentions mediated by cancer fatalism (<i>b</i> = .003, <i>b</i>_<i>p</i> = .003, 95% CI [.001, .004]) and cancer worry (<i>b</i> = .05, <i>b</i>_<i>p</i> = .05, <i>SE</i> = .002, 95% CI [.04, .05]).ConclusionThis study highlights the importance of EHU in promoting cancer screening intentions among older adults in the United States. Access to electronic health information can reduce cancer fatalism and increase cancer worry, ultimately leading to greater interest and intention to undergo cancer screening. These findings have implications for healthcare providers and policymakers aiming to improve cancer screening rates among older adults.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251355831"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Trends in Colorectal Cancer Incidence and Case Numbers among Individuals Aged 45-49 in the US During 2001-2019.","authors":"Chunmei Li, Tianle Chen, Huimin Chen, Bo Zhang, Bing Sun, Pengyang Zhou, Qiken Li, Weiping Chen","doi":"10.1177/10732748251327715","DOIUrl":"10.1177/10732748251327715","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to update the temporal trends for the incidences and case numbers of colorectal cancer (CRC) among individuals aged 45-49 in the US from 2001 to 2019.<b>Methods:</b> Patients were obtained from the National Program of Cancer Registries and Surveillance, Epidemiology and End Results Program (NPCR-SEER) database. Their age-adjusted incidence rates (AAIR) were calculated using the SEER*Stat software.<b>Results:</b> As high as 48.4% (125 604 cases) of the 259 700 early-onset CRC were diagnosed in individuals aged 45-49. Of these, 54.2% were males, and 40.7% were located in the rectum. Adenocarcinoma accounted for 93.9%, 96.5%, and 84.6% of proximal, distal colon, and rectal cancers, respectively. The incidences of proximal colon adenocarcinoma showed a significant increase, with an average annual percentage change (APC) of 0.7 from 2010 to 2019, while the case numbers remained stable from 2001 to 2019. In contrast, distal colon adenocarcinoma displayed increased incidences at an APC of 1.3 and an average increase of 17 cases annually over the study period. Rectal adenocarcinoma showed more rapid increases in incidence, with an average APC of 1.6 and an average increase of 27 cases per year. These rising incidences were predominately observed in non-Hispanic whites (NHWs). Conversely, non-Hispanic black (NHB) females showed decreased incidences of proximal and distal colon adenocarcinoma. Additionally, the incidences and case numbers for carcinoids significantly increased in the rectum but not in the colon.<b>Conclusions:</b> This study reveals distinct patterns of temporal trends in CRC incidences and case numbers among individuals aged 45-49. Further research is necessary to understand the underlying causes of the differences and to develop more effective preventive strategies to reduce the incidence of early-onset CRC.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251327715"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Hybrid Technology-Enabled Financial Navigation Model to Combat Financial Toxicity in Cancer Care.","authors":"Dinesh Pal Mudaranthakam, Allison Makovec, Rachel Forcino, Isuru Ratnayake, Sam Pepper, Stephanie Sherode, Karin Denes-Collar, Anthony D Sung","doi":"10.1177/10732748251387383","DOIUrl":"https://doi.org/10.1177/10732748251387383","url":null,"abstract":"<p><p>Financial toxicity is increasingly recognized as a critical barrier to high-quality cancer care, treatment adherence, and positive survivorship outcomes. Despite the availability of financial and social support resources, patients often face challenges in accessing and navigating them effectively. To address this gap, the University of Kansas Cancer Center developed the Oncology Navigation Empowerment for Treatment (ONCO-NET) platform-an innovative hybrid intervention that integrates an AI-driven resource-matching system with human-centered financial navigation support. Through a structured intake process that includes demographic information, the Functional Assessment of Chronic Illness Therapy Comprehensive Score for Financial Toxicity (FACIT-COST), and social determinants of health data, ONCO-NET identifies and prioritizes the most relevant local resources for each patient. The platform provides real-time, personalized recommendations while offering access to trained financial navigators for additional support. By combining digital technology with human expertise, ONCO-NET enhances accessibility, scalability, and equity in financial navigation. This approach has the potential to improve treatment adherence, reduce disparities, and serve as a scalable model for addressing financial burdens in cancer care and other chronic disease contexts.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251387383"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment.","authors":"Bi Sheng, Dong Wang, Jingjing Wang","doi":"10.1177/10732748241309046","DOIUrl":"10.1177/10732748241309046","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate hepatitis B virus (HBV) reactivation and its effect on tumor response and survival outcomes in patients with HBV-related advanced hepatocellular carcinoma (HCC) undergoing lenvatinib plus camrelizumab treatment.</p><p><strong>Methods: </strong>216 patients with HBV-related advanced HCC receiving lenvatinib and camrelizumab were enrolled. Overall survival (OS), progression-free survival, and tumor response were evaluated. Univariate and multivariate analyses were performed to determine risk factors for HBV reactivation.</p><p><strong>Results: </strong>HBV reactivation occurred in 24 patients (11.1%). It was associated with poor survival and tumor response in these patients. Undetectable DNA levels, the absence of antiviral therapy, and high ALT levels were identified as vital risk factors for HBV reactivation. After receiving or adjusting the antiviral strategy, tumor response improved in patients with HBV reactivation.</p><p><strong>Conclusions: </strong>HBV reactivation could occur in patients with HBV-related HCC, treated with lenvatinib and camrelizumab, worsening tumor response and patient survival. Regular monitoring of the indicators of HBV infection and effective antiviral treatments are recommended for these patients to prevent severe complications.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241309046"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking LEDGF/p75 Overexpression With Microsatellite Instability and KRAS Mutations: A Small-Scale Study in Colorectal Cancer.","authors":"Victoria Liedtke, Thomas Wartmann, Wenjie Shi, Ulf D Kahlert","doi":"10.1177/10732748251313499","DOIUrl":"10.1177/10732748251313499","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) ranks third in men and second in women, with 153,020 new cases and 52,550 deaths in 2023, and with a projected incidence of 2.2 million new cases by 2030 due to lifestyle changes and enhanced diagnostic capabilities. Identification and analysis of new biomarkers, like lens epithelium-derived growth factor splice variant of 75 kDa (LEDGF/p75), which is known to play a crucial role as stress-related oncogene, can make a significant contribution in facilitating early CRC detection.</p><p><strong>Methods: </strong>This study analyzed the expression of LEDGF/p75 and the ubiquitin E2 conjugating enzyme UBC13 in 15 CRC tissue samples and adjacent non-tumor tissues. All patient samples underwent NGS-based mutation analysis beforehand. The western blot technique was used for protein analysis, and the results were further validated using mRNA expression data from 521 patient samples from the TCGA database.</p><p><strong>Results: </strong>LEDGF/p75 expression was significantly elevated in nearly all tumor tissue samples compared to adjacent tissue (11/15, 73.3%). Additionally, the UBC13 enzyme, a key regulator in the degradation of signaling molecules, was also increased in most tumor tissue samples (9/15, 60.0%). Co-overexpression of LEDGF/p75 and UBC13 was evident in 6/6 patients. Patients with KRAS and MSH2 mutations showed a 75% and 100% correlation with LEDGF/p75 overexpression, respectively.</p><p><strong>Conclusion: </strong>This study confirms the upregulation of LEDGF/p75 in CRC and shows its correlation with KRAS and MSH2 mutations. The interaction of LEDGF/p75 with DNA damage response proteins may contribute to drug resistance and increased tumor aggressiveness. LEDGF/p75's potential as a prognostic biomarker independent of lymph node involvement or CEA levels highlights its potential in personalized therapy, and warrants further research into its therapeutic targeting.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251313499"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shooting for the Moon: Can We Cut Cancer Mortality in Canada By 50% By 2050?","authors":"Keaton Banik, Yibing Ruan, Mariet M Stephen, John M Hutchinson, Chantelle Carbonell, Matthew T Warkentin, Andrew Coldman, Rochelle Garner, Hawre Jalal, Darren R Brenner","doi":"10.1177/10732748251319485","DOIUrl":"10.1177/10732748251319485","url":null,"abstract":"<p><strong>Introduction: </strong>The United States of America reignited their Cancer Moonshot Initiative in 2022 with an ambitious goal to reduce cancer mortality by 50% over the next 25 years. In this study, we estimated how and whether a similar cancer control initiative could be achieved in Canada.</p><p><strong>Methods: </strong>We used the OncoSim microsimulation suite to address three questions: (1) what is the expected mortality from cancer in Canada by 2050 given the current trends?; (2) what would be the maximal impact on reducing cancer mortality with prevention and increased screening activities? and, (3) if a 50% reduction in projected cancer mortality could not be achieved through the primary and secondary intervention efforts, what additional advancements and discoveries would be needed to fill the \"lunar gap\"? We modeled the joint impact of risk-factor reduction and screening, as well as the independent effects of prevention and screening alone, on projected cancer mortality.</p><p><strong>Results: </strong>Our models suggest that there will be an expected 133,395 cancer deaths in 2050 in Canada. Approximately 33% of these cancer deaths could be prevented by risk-factor reduction and increased screening programs by the year 2050. This would leave a \"lunar gap\" of about 16%-17% that would need to be bridged with novel discoveries in cancer risk prevention, early detection, and treatment.</p><p><strong>Conclusion: </strong>While current knowledge and implementation of prevention and screening would have a considerable impact on a Canadian cancer moonshot, additional efforts are needed to implement cancer control initiatives and fuel additional discoveries to fill the gap.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251319485"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases.","authors":"Neyran Kertmen, Gozde Kavgaci, Serkan Akin, Gokcen Coban, Ahmet Ilkay Isikay, Gozde Yazici","doi":"10.1177/10732748251322072","DOIUrl":"10.1177/10732748251322072","url":null,"abstract":"<p><strong>Introduction: </strong>Recent advancements in immunotherapy have offered new possibilities for treating aggressive glioblastoma (GBM) and brain metastases. However, evaluating treatment responses remains complex, prompting the development of the immunotherapy-specific Response Assessment in Neuro-Oncology (iRANO) criteria. Herein, we present case reports illustrating the intricacies of interpreting imaging changes post-immunotherapy, emphasizing the need for a comprehensive approach to assessing treatment effectiveness.</p><p><strong>Case reports: </strong>Case 1 discusses a 41-year-old male with GBM, highlighting the challenges of differentiating tumor progression from treatment-induced pseudoprogression. Case 2 discusses a 45-year-old female with brain metastatic malignant melanoma, presenting radiological evidence of progressive disease while undergoing nivolumab treatment. Case 3 discusses a 37-year-old male with GBM, where radiological evidence indicates progressive disease while receiving pembrolizumab treatment.</p><p><strong>Management and outcomes: </strong>In case 1, we discussed the challenges of distinguishing true tumor progression from treatment-induced pseudoprogression, leading to the continuation of the same treatment due to pseudoprogression. In case 2, post-surgery pathology revealed radionecrosis and treatment-related changes, guiding the continuation of nivolumab therapy. Case 3 involved a pathologically confirmed progression, and the patient received best supportive care due to his performance status.</p><p><strong>Discussion: </strong>Despite aggressive treatment regimens, the prognosis for GBM patients remains poor, underscoring the necessity for innovative therapeutic strategies. Immunotherapy holds promise in reshaping the treatment landscape for GBM and brain metastases, but further research and refinement of assessment criteria are crucial. Throughout our cases, we discuss the iRANO criteria, developed to overcome the limitations of the RANO criteria in capturing immunotherapy responses, particularly pseudoprogression.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251322072"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Contributing to Late Breast Cancer Diagnosis at the Brazzaville University Hospital in 2020, Congo: A Cross-Sectional Analytic Study.","authors":"Michel Ilboudo, Sylvain Honoré Woromogo, Dagnagnéwendé Dieudonné Kaboré, Nina Assanatou Jumelle Zerbo, Jean Bernard Nkoua Mbon","doi":"10.1177/10732748241270634","DOIUrl":"10.1177/10732748241270634","url":null,"abstract":"<p><strong>Objectives: </strong>Breast cancer is leading the cancer incidence and mortality ranks worldwide. Currently, breast cancer represents 30.1% of all cancers occurring in women in Congo. In sub-Saharan Africa, breast cancer is diagnosed delayed in 70% of cases. The purpose of this work is to study the epidemiological aspects of patients with late diagnosis of breast cancer at the Brazzaville University Hospital, Congo.</p><p><strong>Methods: </strong>We carried out a cross-sectional analytic study in the medical oncology service of the University Hospital of Brazzaville. We used systematic, exhaustive sampling. Logistic regression was used for data analysis, and <i>P</i> values ≤5% were considered significant.</p><p><strong>Results: </strong>Data for 182 patients were collected. Delay in diagnosis represented 91.21% of cases. Delay in diagnosis was significantly associated with lack of finance (<i>P</i> = 0.011) and with breast cancer stages greater than 2 (<i>P</i> < 0.001), but the proximity to the center was suggestive. Multivariate analysis revealed an association between diagnostic delay and proximity to the center (<i>P</i> = 0.025) as well as with breast cancer stages greater than 2 (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>The delay in breast cancer diagnosis widely discussed in the literature remains relevant in Congo. Routine screening, the construction of a cancer center and its optimal equipment, and the subsidy of care are all critical factors for battling delayed breast cancer diagnosis in Congo.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241270634"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study.","authors":"Yi Peng, De Wu, Jing Tang, Xiaobing Li","doi":"10.1177/10732748251318383","DOIUrl":"10.1177/10732748251318383","url":null,"abstract":"<p><strong>Objective: </strong>To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC).</p><p><strong>Materials and methods: </strong>We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy. These patients subsequently received maintenance therapy (MT) with a combination of anlotinib and PD-1/L1 inhibitors. The primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs).</p><p><strong>Results: </strong>Preliminary findings suggest that this regimen is highly effective, with a median PFS of 6 months and OS of 13.5 months, alongside a DCR exceeding 60%. Subgroup analysis revealed enhanced efficacy in patients with fewer than three metastatic sites and those who experienced hypertension, proteinuria, or hand-foot syndrome during MT. Mechanistic studies showed a notable increase in the proportion of CD8+ T cells in the peripheral blood post-MT, correlating with improved outcomes. These findings imply that the therapeutic effect of MT may be partly due to the direct activation of CD8+ T cells, producing a synergistic anti-tumor response. Despite the prevalence of AEs, AEs were generally manageable, underscoring anlotinib's potential in this context.</p><p><strong>Conclusion: </strong>The combination of anlotinib and PD-1/L1 inhibitors offers promising efficacy and manageable AEs in MT, making it a viable option for ES-SCLC patients who achieve SD post-initial therapy. These results justify further prospective studies to validate this approach.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318383"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}